Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Prima Biomed Ltd's CVAC GRANTED secures Fast Track Designation by FDA


Thursday, 8 May 2014 08:00pm EDT 

Prima Biomed Ltd:Says that the United States Food and Drug Administration granted Fast Track Designation to the CVac clinical development program at Prima.This program is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer who enter a second complete remission.Prima will work closely with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the U.S. 

Company Quote

0.033
-0.0010 -2.94%
23 Jan 2015